Literature DB >> 30680732

The innate immune architecture of lung tumors and its implication in disease progression.

Simon Milette1,2, Pierre O Fiset3, Logan A Walsh2,4, Jonathan D Spicer1,2,5, Daniela F Quail1,2,6.   

Abstract

Lung malignancies are the leading cause of cancer-related mortality. By virtue of its unique physiological function, the lung microenvironment is highly dynamic and constantly subjected to mechanical, chemical and pathogenic stimuli. Thus, the airways rely on highly organized innate defense mechanisms to rapidly protect against pathogens and maintain pulmonary homeostasis. However, in the context of lung malignancy, these defenses often provide collateral inflammatory insults that can foster tumor progression. This review summarizes the interactions between cancer cells, recruited immune cells and tissue-resident cell subpopulations, such as airway epithelial cells and alveolar macrophages, during homeostasis and disease. Furthermore, we examine the role of the lung immune landscape in response to current therapeutic interventions for cancer. Given the prevalence of lung malignancies, we propose that consideration of lung physiology as a whole is necessary to understand and treat these lethal diseases.
Copyright © 2019 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. Copyright © 2019 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  Tumor microenvironment; immunotherapy; innate immunity; lung cancer

Year:  2019        PMID: 30680732     DOI: 10.1002/path.5241

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  17 in total

1.  Methylation Regulation of TLR3 on Immune Parameters in Lung Adenocarcinoma.

Authors:  Ang Li; Hongjiao Wu; Qinqin Tian; Yi Zhang; Zhi Zhang; Xuemei Zhang
Journal:  Front Oncol       Date:  2021-05-20       Impact factor: 6.244

2.  Testing for COVID-19 in lung cancer patients.

Authors:  A Passaro; S Peters; T S K Mok; I Attili; T Mitsudomi; F de Marinis
Journal:  Ann Oncol       Date:  2020-04-09       Impact factor: 32.976

Review 3.  Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment.

Authors:  Sara Saab; Hussein Zalzale; Zahraa Rahal; Yara Khalifeh; Ansam Sinjab; Humam Kadara
Journal:  Front Immunol       Date:  2020-02-11       Impact factor: 7.561

Review 4.  Myeloid-derived suppressor cells-new and exciting players in lung cancer.

Authors:  Zhenzhen Yang; Jiacheng Guo; Lanling Weng; Wenxue Tang; Shuiling Jin; Wang Ma
Journal:  J Hematol Oncol       Date:  2020-01-31       Impact factor: 17.388

5.  Targeting Erbin in B cells for therapy of lung metastasis of colorectal cancer.

Authors:  Tong Shen; Jing-Lin Liu; Chu-Yi Wang; Youlutuziayi Rixiati; Shi Li; Ling-Dong Cai; Yuan-Yuan Zhao; Jian-Ming Li
Journal:  Signal Transduct Target Ther       Date:  2021-03-12

6.  Ganoderma lucidum polysaccharide (GLP) enhances antitumor immune response by regulating differentiation and inhibition of MDSCs via a CARD9-NF-κB-IDO pathway.

Authors:  Yongyong Wang; Xiaowu Fan; Xiaowei Wu
Journal:  Biosci Rep       Date:  2020-06-26       Impact factor: 3.840

7.  Immune regulatory markers of lepidic-pattern adenocarcinomas presenting as ground glass opacities.

Authors:  David B Nelson; Kyle G Mitchell; Jing Wang; Junya Fujimoto; Myrna Godoy; Carmen Behrens; Xiaofeng Zheng; Jianjun Zhang; Boris Sepesi; Ara A Vaporciyan; Wayne L Hofstetter; Reza J Mehran; David C Rice; Garrett L Walsh; Stephen G Swisher; Cesar A Moran; Neda Kalhor; Annikka Weissferdt; Ignacio I Wistuba; Jack A Roth; Mara B Antonoff
Journal:  J Thorac Dis       Date:  2020-03       Impact factor: 3.005

Review 8.  The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion.

Authors:  Paola De Cicco; Giuseppe Ercolano; Angela Ianaro
Journal:  Front Immunol       Date:  2020-07-30       Impact factor: 7.561

9.  Lesson of the month: novel method to quantify neutrophil uptake in early lung cancer using SPECT-CT.

Authors:  Neda Farahi; Daniel Gillett; Mark Southwood; Doris Rassl; Nicola Tregay; Uta Hill; Stephen Denis Preston; Chrystalla Loutsios; Laurence Si Chong Lok; Sarah Heard; John Buscombe; Robert Campbell Rintoul; A Michael Peters; Charlotte Summers; Edwin R Chilvers
Journal:  Thorax       Date:  2020-09-04       Impact factor: 9.139

10.  Single-cell RNA sequencing reveals heterogeneous tumor and immune cell populations in early-stage lung adenocarcinomas harboring EGFR mutations.

Authors:  Xianmin Zhu; Peng Zhang; Guoping Fan; Di He; Di Wang; Ping Lu; Nan Yang; Zhigang Xue
Journal:  Oncogene       Date:  2020-11-03       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.